pharmaphorum

DECEMBER 4, 2020

This investigational multivalent protein subunit vaccine targets the outer surface protein A (OspA) of the bacterium Borrelia that causes the disease, an established mechanism of action for a Lyme disease vaccine. VLA15 has demonstrated a promising immune response and safety data in pre-clinical and clinical studies so far.

Vaccination 119

Vaccination Vaccine Bacterium Protein 119

XTalks

NOVEMBER 6, 2020

Symvivo’s bacTRL Gene Therapy Platform is designed and optimized to address limitations associated with typical vaccines, including the inability to accommodate large or multiple genes, lack of specificity to targeted tissue and poor control over immune response, says the company.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

pharmaphorum

JULY 14, 2021

The shot also includes two “conserved” pneumococcal proteins – antigens that seem always to be present in the bacterium regardless of its serotype, so could potentially provide protection against an even broader range.

Immune Response 52

Immune Response Vaccine Vaccination Protein 52

XTalks

JANUARY 20, 2021

While diseases like celiac are associated with inappropriate activation of the immune system triggered by food antigens, this is not the case in IBS. In a normal, healthy intestine, foods do not trigger immune responses and so in a patient with IBS, something else must activate the response. Mouse and Human Studies.

Immune Response 52

Immune Response Research Allergies Protein 52

pharmaphorum

MAY 31, 2022

With ASP3772, GSK could offer a shot with broader coverage of pneumococcal serotypes than any of its rivals, and which also includes two “conserved” pneumococcal proteins – antigens that seem always to be present in the bacterium regardless of its serotype.

Vaccine 52

Vaccine Vaccination Bacterium Sales 52

The Pharma Data

JUNE 2, 2022

Affinivax’s most advanced vaccine candidate (AFX3772) includes 24 pneumococcal polysaccharides plus two conserved pneumococcal proteins (compared to up to 20 serotypes in currently approved vaccines). The bacterium Streptococcus pneumoniae causes pneumococcal disease. About Pneumococcal disease.

Vaccine 52

Vaccine Vaccination Immune Response Protein 52

The Pharma Data

MAY 31, 2022

Affinivax’s most advanced vaccine candidate (AFX3772) includes 24 pneumococcal polysaccharides plus two conserved pneumococcal proteins (compared to up to 20 serotypes in currently approved vaccines). The bacterium Streptococcus pneumoniae causes pneumococcal disease. CAGR: Compound Annual Growth Rate; **CER: Constant Exchange Rate.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52